Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Genzyme Closes Pharma Intermediates Business Sale

By Pharmaceutical Processing | March 1, 2011

CAMBRIDGE,
Mass. (AP) —Genzyme Corp. said today
that it completed the sale of its pharmaceutical intermediates business,
finishing a plan announced last year to sell three businesses so it can focus
on core growth areas.

The Cambridge,
Mass., company did not disclose
terms of the business sale to International Chemical Investors Group. Genzyme
said it entered into a supply contract with the buyer to receive materials
needed to produce a potential Gaucher disease treatment in late-stage clinical
testing. Gaucher disease is an enzyme disorder that can result in liver and
neurological problems.

Genzyme is being acquired by French drugmaker Sanofi-Aventis
SA. Last month, Sanofi said it would pay $20.1 billion, or $74 per share,
ending months of haggling between the two companies over a possible deal.

Genzyme, which was founded in the 1980s, grew into a biotech
powerhouse in the 1990s after launching Ceredase, the first treatment for
Gaucher’s disease. By 2008 the company was reporting sales of $4.6 billion, but
a series of manufacturing stumbles the following year left the company
vulnerable to takeover.

Last May, before reports of a possible Sanofi deal surfaced,
Genzyme had said it would sell its pharmaceutical intermediates business, as
well as its genetic testing and diagnostics products businesses, as part of a
plan to increase shareholder value.

Genzyme shares climbed 7 cents to $75.52 in late morning
trading.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE